Spots Global Cancer Trial Database for urethral cancer
Every month we try and update this database with for urethral cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| S0031, ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract | NCT00014144 | Bladder Cancer Transitional Ce... Urethral Cancer | gefitinib | - | SWOG Cancer Research Network | |
| Short-Term Low-Dose Interferon Alfa in Treating Patients With Cancer of the Urothelium | NCT00082719 | Bladder Cancer Urethral Cancer | Recombinant Int... | - | M.D. Anderson Cancer Center | |
| S0306, Irinotecan in Treating Patients With Recurrent or Refractory Advanced Transitional Cell Cancer of the Urothelium Previously Treated With Chemotherapy | NCT00066612 | Bladder Cancer Transitional Ce... Urethral Cancer | irinotecan hydr... | 18 Years - | SWOG Cancer Research Network | |
| S0219, Combination Chemotherapy Followed By Observation or Surgery in Patients With Stage II or Stage III Cancer of the Urothelium | NCT00045630 | Bladder Cancer Transitional Ce... Urethral Cancer | carboplatin gemcitabine paclitaxel surgery | 18 Years - | SWOG Cancer Research Network | |
| Combination Chemotherapy in Treating Patients With Bladder Cancer | NCT00003701 | Bladder Cancer Urethral Cancer | carboplatin cisplatin doxorubicin hyd... methotrexate paclitaxel vinblastine sul... | 0 Years - 120 Years | Eastern Cooperative Oncology Group | |
| Sunitinib Malate in Treating Patients With Locally Recurrent, Locally Advanced, Unresectable, or Metastatic Urinary Tract Cancer | NCT01118039 | Bladder Cancer Transitional Ce... Urethral Cancer | sunitinib malat... immunohistochem... laboratory biom... pharmacological... quality-of-life... | 18 Years - | National Cancer Institute (NCI) | |
| Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract Cancer | NCT01191892 | Bladder Cancer Transitional Ce... Ureter Cancer Urethral Cancer | carboplatin gemcitabine hyd... vandetanib Placebo | 18 Years - 120 Years | Cardiff University | |
| Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma | NCT03179943 | Urothelial Carc... | Atezolizumab Guadecitabine | 18 Years - | Fox Chase Cancer Center | |
| Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma | NCT03291028 | Renal Cell Carc... Urothelial Carc... Bladder Cancer Ureter Cancer Urethral Cancer | Immune checkpoi... | - | Fox Chase Cancer Center | |
| UC-GENOME: Urothelial Cancer-GENOmic Analysis to iMprove Patient Outcomes and rEsearch | NCT02643043 | Urothelial Carc... Bladder Cancer Urethral Cancer Cancer of the U... | Biospecimen Col... | 18 Years - | Hoosier Cancer Research Network | |
| DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma | NCT01353222 | Urothelial Carc... | DN24-02 Standard of Car... | 18 Years - | Dendreon | |
| Two-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium | NCT00003376 | Bladder Cancer Transitional Ce... Urethral Cancer | carboplatin cisplatin doxorubicin hyd... methotrexate paclitaxel vinblastine | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| Combination Chemotherapy in Treating Patients With Bladder Cancer | NCT00003701 | Bladder Cancer Urethral Cancer | carboplatin cisplatin doxorubicin hyd... methotrexate paclitaxel vinblastine sul... | 0 Years - 120 Years | Eastern Cooperative Oncology Group | |
| Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant | NCT00082706 | Bladder Cancer Urethral Cancer Urachal Cancer | 5-Fluorouracil ... Leucovorin Cisplatin Gemcitabine | 18 Years - | M.D. Anderson Cancer Center | |
| 64Cu-GRIP B in Patients With Advanced Malignancies | NCT05888532 | Prostate Cancer Renal Cancer Urethral Cancer Advanced Solid ... Metastatic Cast... Solid Tumor, Ad... | Copper-64 label... Positron Emissi... | 18 Years - | University of California, San Francisco | |
| Sunitinib Malate in Treating Patients With Locally Recurrent, Locally Advanced, Unresectable, or Metastatic Urinary Tract Cancer | NCT01118039 | Bladder Cancer Transitional Ce... Urethral Cancer | sunitinib malat... immunohistochem... laboratory biom... pharmacological... quality-of-life... | 18 Years - | National Cancer Institute (NCI) | |
| Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid Tumors | NCT01352962 | Urethral Neopla... Neoplasms, Uret... Cancer of the U... Urethral Cancer | Gemcitabine Carboplatin Lenalidomide | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium and Decreased Kidney Function | NCT00005644 | Bladder Cancer Transitional Ce... Urethral Cancer | gemcitabine hyd... paclitaxel | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| Fluorouracil in Treating Patients With Recurrent or Metastatic Bladder Cancer | NCT00003175 | Bladder Cancer Transitional Ce... Urethral Cancer | fluorouracil | - | National Cancer Institute (NCI) | |
| Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant | NCT00082706 | Bladder Cancer Urethral Cancer Urachal Cancer | 5-Fluorouracil ... Leucovorin Cisplatin Gemcitabine | 18 Years - | M.D. Anderson Cancer Center | |
| Four Cycles Versus Six Cycles of Cisplatin-based Chemotherapy in Metastatic Urothelial Carcinoma | NCT03296306 | Bladder Cancer Ureter Cancer Urethral Cancer Transitional Ce... | Treatment durat... | 18 Years - | Asan Medical Center | |
| Gemcitabine Hydrochloride, Cisplatin, and Sunitinib Malate as First-Line Therapy in Treating Patients With Locally Advanced And/or Metastatic Transitional Cell Carcinoma of the Urothelium (SUCCINCT) | NCT01089088 | Bladder Cancer Transitional Ce... Urethral Cancer | cisplatin gemcitabine hyd... sunitinib malat... | 16 Years - 120 Years | Cardiff University | |
| Four Cycles Versus Six Cycles of Cisplatin-based Chemotherapy in Metastatic Urothelial Carcinoma | NCT03296306 | Bladder Cancer Ureter Cancer Urethral Cancer Transitional Ce... | Treatment durat... | 18 Years - | Asan Medical Center | |
| Biomarkers in Patients With Kidney Cancer or Cancer of the Urothelium and in Healthy Participants | NCT00900276 | Bladder Cancer Kidney Cancer Transitional Ce... Urethral Cancer | immunologic tec... laboratory biom... mass spectromet... | 18 Years - 120 Years | Wake Forest University Health Sciences | |
| Videoscopic Versus Open Inguinal Lymphadenectomy for Cancer | NCT01526486 | Melanoma Merkel Cell Car... Squamous Cell C... Penile Carcinom... Urethral Carcin... Extramammary Pa... Scrotal Carcino... Anal Cancer Vulvar Cancer Skin Cancer Lymphadenopathy | Videoscopic pro... Open, tradition... | 18 Years - 80 Years | Emory University | |
| Docetaxel and Gemcitabine in Treating Patients With Progressive Regional or Metastatic Bladder Cancer | NCT00004223 | Bladder Cancer Transitional Ce... Urethral Cancer | docetaxel gemcitabine hyd... | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| UC-GENOME: Urothelial Cancer-GENOmic Analysis to iMprove Patient Outcomes and rEsearch | NCT02643043 | Urothelial Carc... Bladder Cancer Urethral Cancer Cancer of the U... | Biospecimen Col... | 18 Years - | Hoosier Cancer Research Network | |
| Gemcitabine Hydrochloride, Cisplatin, and Temsirolimus as First-Line Therapy in Treating Patients With Locally Advanced and/or Metastatic Transitional Cell Cancer of the Urothelium | NCT01090466 | Bladder Cancer Transitional Ce... Urethral Cancer | cisplatin gemcitabine hyd... temsirolimus pharmacological... | 16 Years - 120 Years | Cardiff University | |
| Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium and Decreased Kidney Function | NCT00005644 | Bladder Cancer Transitional Ce... Urethral Cancer | gemcitabine hyd... paclitaxel | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors | NCT00479128 | Solid Tumor Urethral Cancer | Bortezomib Gemcitabine Doxorubicin | - | M.D. Anderson Cancer Center | |
| Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid Tumors | NCT01352962 | Urethral Neopla... Neoplasms, Uret... Cancer of the U... Urethral Cancer | Gemcitabine Carboplatin Lenalidomide | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| SCH 66336 Plus Gemcitabine in Treating Patients With Advanced Cancer of the Urinary Tract | NCT00006351 | Bladder Cancer Transitional Ce... Urethral Cancer | gemcitabine hyd... lonafarnib | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Pemetrexed Disodium and Gemcitabine in Treating Patients With Advanced Cancer of the Urothelium | NCT00053209 | Bladder Cancer Transitional Ce... Urethral Cancer | gemcitabine hyd... pemetrexed diso... | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| Pazopanib Hydrochloride in Treating Patients With Metastatic Urethral Cancer or Bladder Cancer That Has Relapsed or Not Responded to Treatment | NCT01031875 | Bladder Cancer Transitional Ce... Urethral Cancer | pazopanib hydro... fludeoxyglucose... | 18 Years - | National Cancer Institute (NCI) | |
| DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma | NCT01353222 | Urothelial Carc... | DN24-02 Standard of Car... | 18 Years - | Dendreon | |
| Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium | NCT00397488 | Bladder Cancer Transitional Ce... Urethral Cancer | sunitinib malat... | 18 Years - 120 Years | Memorial Sloan Kettering Cancer Center | |
| Sunitinib Malate in Treating Patients With Locally Recurrent, Locally Advanced, Unresectable, or Metastatic Urinary Tract Cancer | NCT01118039 | Bladder Cancer Transitional Ce... Urethral Cancer | sunitinib malat... immunohistochem... laboratory biom... pharmacological... quality-of-life... | 18 Years - | National Cancer Institute (NCI) | |
| A Novel Imaging Protocol in Use to Identify Lymph Nodes and Organs of Interest | NCT05899361 | Urologic Cancer Urologic Neopla... Bladder Cancer Prostate Cancer Testicular Canc... Kidney Cancer Urethral Cancer Penile Cancer | Electromagnetic... Ultrasound | 18 Years - | Dana-Farber Cancer Institute | |
| Cisplatin Plus Gemcitabine With or Without Paclitaxel in Treating Patients With Stage IV Urinary Tract Cancer | NCT00022191 | Bladder Cancer Transitional Ce... Urethral Cancer | cisplatin gemcitabine hyd... paclitaxel | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| S0219, Combination Chemotherapy Followed By Observation or Surgery in Patients With Stage II or Stage III Cancer of the Urothelium | NCT00045630 | Bladder Cancer Transitional Ce... Urethral Cancer | carboplatin gemcitabine paclitaxel surgery | 18 Years - | SWOG Cancer Research Network | |
| A Novel Imaging Protocol in Use to Identify Lymph Nodes and Organs of Interest | NCT05899361 | Urologic Cancer Urologic Neopla... Bladder Cancer Prostate Cancer Testicular Canc... Kidney Cancer Urethral Cancer Penile Cancer | Electromagnetic... Ultrasound | 18 Years - | Dana-Farber Cancer Institute | |
| Combination Chemotherapy in Patients With Advanced Urinary Tract Cancer | NCT00002684 | Bladder Cancer Urethral Cancer | cisplatin ifosfamide paclitaxel | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Combination Chemotherapy in Treating Patients With Bladder Cancer | NCT00003701 | Bladder Cancer Urethral Cancer | carboplatin cisplatin doxorubicin hyd... methotrexate paclitaxel vinblastine sul... | 0 Years - 120 Years | Eastern Cooperative Oncology Group | |
| Nitrocamptothecin in Treating Patients With Metastatic Cancer of the Urinary Tract | NCT00006026 | Bladder Cancer Transitional Ce... Urethral Cancer | rubitecan | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Surgery Plus Combination Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Urinary Tract | NCT00006111 | Bladder Cancer Transitional Ce... Urethral Cancer | cisplatin fluorouracil conventional su... radiation thera... | 18 Years - 70 Years | UNICANCER | |
| Videoscopic Versus Open Inguinal Lymphadenectomy for Cancer | NCT01526486 | Melanoma Merkel Cell Car... Squamous Cell C... Penile Carcinom... Urethral Carcin... Extramammary Pa... Scrotal Carcino... Anal Cancer Vulvar Cancer Skin Cancer Lymphadenopathy | Videoscopic pro... Open, tradition... | 18 Years - 80 Years | Emory University | |
| S0031, ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract | NCT00014144 | Bladder Cancer Transitional Ce... Urethral Cancer | gefitinib | - | SWOG Cancer Research Network | |
| Integrated Cancer Repository for Cancer Research | NCT02012699 | Pancreatic Canc... Thyroid Cancer Lung Cancer Esophageal Canc... Thymus Cancer Colon Cancer Rectal Cancer Gastrointestina... Anal Cancer Bile Duct Cance... Duodenal Cancer Gallbladder Can... Gastric Cancer Liver Cancer Small Intestine... Peritoneal Surf... Familial Adenom... Lynch Syndrome Bladder Cancer Kidney Cancer Penile Cancer Prostate Cancer Testicular Canc... Ureter Cancer Urethral Cancer Hypopharyngeal ... Laryngeal Cance... Lip Cancer Oral Cavity Can... Nasopharyngeal ... Oropharyngeal C... Paranasal Sinus... Nasal Cavity Ca... Salivary Gland ... Skin Cancer Central Nervous... Central Nervous... Mesothelioma Breast Cancer Leukemia Melanoma Sarcoma Unknown Primary... Multiple Myelom... Ovarian Cancer Endometrial Can... Vaginal Cancer Neuroendocrine ... Plasma Cell Dys... Healthy Control | 19 Years - 110 Years | University of Nebraska | ||
| Gemcitabine Hydrochloride, Cisplatin, and Temsirolimus as First-Line Therapy in Treating Patients With Locally Advanced and/or Metastatic Transitional Cell Cancer of the Urothelium | NCT01090466 | Bladder Cancer Transitional Ce... Urethral Cancer | cisplatin gemcitabine hyd... temsirolimus pharmacological... | 16 Years - 120 Years | Cardiff University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
